Overview

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Status:
RECRUITING

Trial end date:
2029-05-30

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)

Phase:

PHASE3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

bimekizumab